Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Title
Intervention Indication Therapeutic Area Year Actions
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer Selpercatinib (LOXO-292; LY3527723) Thyroid cancer Oncology 2022 View  |  Download
Selpercatinib for previously untreated medullary thyroid cancer with RET mutation in patients ages 12 and older Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) Head and Neck Cancer 2022 View  |  Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Selumetinib for neurofibromatosis type 1 Selumetinib (AZD6244; ARRY-142886) Neurofibromatosis Neurology 2019 View  |  Download
Selumetinib for treating symptomatic, inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in adults Selumetinib (AZD6244; ARRY-142886) Plexiform neurofibromas Neurological Cancer , Neurology 2023 View  |  Download
Semaglutide for non-cirrhotic non-alcoholic steatohepatitis Semaglutide (Ozempic) Non-alcoholic steatohepatitis (NASH) Hepatology 2023 View  |  Download
Semaglutide for overweight individuals ATB200/AT2221 , Semaglutide (Ozempic) Obesity , Weight management Endocrine Nutritional and Metabolic Disorders 2020 View  |  Download
Semaglutide for treating obesity-related heart failure Semaglutide (Ozempic) Obesity-related heart failure Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Semaglutide for treating overweight and obesity Semaglutide (Ozempic) Obesity Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
1 2 90 91 92 93 94 111 112
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications